Japanese Clinical Practice Guideline for Diabetes 2019

Eiichi Araki; Atsushi Goto; Tatsuya Kondo; Mitsuhiko Noda; Hiroshi Noto; Hideki Origasa; Haruhiko Osawa; Akihiko Taguchi; Yukio Tanizawa; Kazuyuki Tobe; Narihito Yoshioka

doi:10.1111/jdi.13306

Japanese Clinical Practice Guideline for Diabetes 2019

Eiichi Araki^*, Atsushi Goto, Tatsuya Kondo, Mitsuhiko Noda, Hiroshi Noto, Hideki Origasa, Haruhiko Osawa, Akihiko Taguchi, Yukio Tanizawa, Kazuyuki Tobe, Narihito Yoshioka

^*Corresponding author for this work

Internal Medicine （1）

Research output: Contribution to journal › Article › peer-review

219 Scopus citations

Original language	English
Pages (from-to)	1020-1076
Number of pages	57
Journal	Journal of Diabetes Investigation
Volume	11
Issue number	4
DOIs	https://doi.org/10.1111/jdi.13306
State	Published - 2020/07/01

Keywords

Diabetes
Diagnosis
Guideline
Treatment

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1111/jdi.13306

Cite this

@article{d0bc649cd74d403c8526a057bf6cfd8f,

title = "Japanese Clinical Practice Guideline for Diabetes 2019",

keywords = "Diabetes, Diagnosis, Guideline, Treatment",

author = "Eiichi Araki and Atsushi Goto and Tatsuya Kondo and Mitsuhiko Noda and Hiroshi Noto and Hideki Origasa and Haruhiko Osawa and Akihiko Taguchi and Yukio Tanizawa and Kazuyuki Tobe and Narihito Yoshioka",

note = "Funding Information: Eiichi Araki received honoraria from AstraZeneca, Daiichi Sankyo, Kowa, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk, Ono Pharmaceutical and Sanofi, also received subsidies or donations from Astellas Pharma, Bayer Yakuhin, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Novo Nordisk, Pfizer Japan, Sanofi, Sumitomo Dainippon Pharma, Taisho Pharmaceutical and Takeda Pharmaceutical, and belongs to endowed departments by MSD, Ono Pharmaceutical and Terumo. Mitsuhiko Noda received subsidies or donations from Astellas Pharma, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly Japan, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk Pharma, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical and Teijin Pharma. Hiroshi Noto received honoraria from Eli Lilly Japan and MSD. Haruhiko Osawa received research funding from Daiichi Sankyo, Ono Pharmaceutical, Sysmex, Taisho Toyama Pharmaceutical and Takeda Pharmaceutical. Yukio Tanizawa received honoraria from Astellas Pharma, MSD, Novo Nordisk Pharma, Ono Pharmaceutical and Takeda Pharmaceutical, also received research funding from Seastar, also received subsidies or donations from Astellas Pharma, Daiichi Sankyo, Eli Lilly Japan, Kyowa Kirin, Mitsubishi Tanabe Pharma, MSD, Nippon Boehringer Ingelheim, Sanofi, Sumitomo Dainippon Pharma and Takeda Pharmaceutical. Kazuyuki Tobe received honoraria from Novo Nordisk Pharma, Kowa Pharmaceutical and Astellas Pharma, also received research funding from The Uehara Memorial Foundation and The Naito Foundation, also received subsidies or donations from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Daiichi Sankyo, MSD, Asahi Kasei Pharma, Teijin Pharma, Boehringer Ingelheim, Ono Pharmaceutical, Novo Nordisk Pharma, Eli Lilly Japan, Fuji Chemical Industries and Arkray. Narihito Yoshioka received honoraria from Novo Nordisk Pharma and Takeda Pharmaceutical. Atsushi Goto, Tatsuya Kondo, Hideki Origasa, Akihiko Taguchi have nothing to declare. ",

year = "2020",

month = jul,

day = "1",

doi = "10.1111/jdi.13306",

language = "英語",

volume = "11",

pages = "1020--1076",

journal = "Journal of Diabetes Investigation",

issn = "2040-1116",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Japanese Clinical Practice Guideline for Diabetes 2019

AU - Araki, Eiichi

AU - Goto, Atsushi

AU - Kondo, Tatsuya

AU - Noda, Mitsuhiko

AU - Noto, Hiroshi

AU - Origasa, Hideki

AU - Osawa, Haruhiko

AU - Taguchi, Akihiko

AU - Tanizawa, Yukio

AU - Tobe, Kazuyuki

AU - Yoshioka, Narihito

N1 - Funding Information: Eiichi Araki received honoraria from AstraZeneca, Daiichi Sankyo, Kowa, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk, Ono Pharmaceutical and Sanofi, also received subsidies or donations from Astellas Pharma, Bayer Yakuhin, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Novo Nordisk, Pfizer Japan, Sanofi, Sumitomo Dainippon Pharma, Taisho Pharmaceutical and Takeda Pharmaceutical, and belongs to endowed departments by MSD, Ono Pharmaceutical and Terumo. Mitsuhiko Noda received subsidies or donations from Astellas Pharma, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly Japan, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk Pharma, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical and Teijin Pharma. Hiroshi Noto received honoraria from Eli Lilly Japan and MSD. Haruhiko Osawa received research funding from Daiichi Sankyo, Ono Pharmaceutical, Sysmex, Taisho Toyama Pharmaceutical and Takeda Pharmaceutical. Yukio Tanizawa received honoraria from Astellas Pharma, MSD, Novo Nordisk Pharma, Ono Pharmaceutical and Takeda Pharmaceutical, also received research funding from Seastar, also received subsidies or donations from Astellas Pharma, Daiichi Sankyo, Eli Lilly Japan, Kyowa Kirin, Mitsubishi Tanabe Pharma, MSD, Nippon Boehringer Ingelheim, Sanofi, Sumitomo Dainippon Pharma and Takeda Pharmaceutical. Kazuyuki Tobe received honoraria from Novo Nordisk Pharma, Kowa Pharmaceutical and Astellas Pharma, also received research funding from The Uehara Memorial Foundation and The Naito Foundation, also received subsidies or donations from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Daiichi Sankyo, MSD, Asahi Kasei Pharma, Teijin Pharma, Boehringer Ingelheim, Ono Pharmaceutical, Novo Nordisk Pharma, Eli Lilly Japan, Fuji Chemical Industries and Arkray. Narihito Yoshioka received honoraria from Novo Nordisk Pharma and Takeda Pharmaceutical. Atsushi Goto, Tatsuya Kondo, Hideki Origasa, Akihiko Taguchi have nothing to declare.

PY - 2020/7/1

Y1 - 2020/7/1

KW - Diabetes

KW - Diagnosis

KW - Guideline

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85088377956&partnerID=8YFLogxK

U2 - 10.1111/jdi.13306

DO - 10.1111/jdi.13306

M3 - 学術論文

C2 - 33021749

AN - SCOPUS:85088377956

SN - 2040-1116

VL - 11

SP - 1020

EP - 1076

JO - Journal of Diabetes Investigation

JF - Journal of Diabetes Investigation

IS - 4

ER -